





PHARMACEUTICAL 2021

Immune Therapeutics Inc. Rank 293 of 409

The relative strengths and weaknesses of Immune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 789% points. The greatest weakness of Immune Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -281%, being 73% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	10.0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,677
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	0.64
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	126
Revenues	0
Selling, General and Administrative Expense	760

Output Variable	Value in 1000 USD
Assets	10
Liabilities	11,677
Expenses	887
Stockholders Equity	-11,667
Net Income	-887
Comprehensive Net Income	-887
Economic Capital Ratio	-281%

